Key facts
- Notable investors include Tech Incubator Program for Startup, Samsung Venture Investment, Smilegate Investment, Matter (Consulting Services (B2B)), Kakao Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for NeuroXT
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroXT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroXT
Developer of precision diagnosis software intended to predict molecular pathology values. The company uses magnetic resonance imaging (MRI) images to analyze a specific treatment drug's effects or side effects on the patient to determine suitability, enabling the healthcare sector to benefit from precision treatment for degenerative brain diseases based on various image analysis experiences.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Employees
- 28
- Website
- neuroxt.com/
- Ownership
- Privately Held (backing)
NeuroXT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroXT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroXT in its N-PORT filings yet. We sweep new filings monthly.